Apremilast
CC-10004-PPP-001
Phase 2 small_molecule completed
Quick answer
Apremilast for Palmoplantaris Pustulosis is a Phase 2 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Palmoplantaris Pustulosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed